[1]
|
TOKITA K, SCHMID K. Variants of alpha-1-acid glycoprotein[J]. Nature,1963,200:266. doi: 10.1038/200266a0 |
[2]
|
FOURNIER T, MEDJOUBI-N N, PORQUET D. Alpha-1-acid glycoprotein[J]. Biochim Biophys Acta,2000,1482(1-2):157-171. doi: 10.1016/S0167-4838(00)00153-9 |
[3]
|
HEEGAARD P M, MILLER I, SORENSEN N S, et al. Pig α1-acid glycoprotein: characterization and first description in any species as a negative acute phase protein[J]. PLoS One,2013,8(7):e68110. doi: 10.1371/journal.pone.0068110 |
[4]
|
BLAIN P G, MUCKLOW J C, RAWLINS M D, et al. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health[J]. Br J Clin Pharmacol,1985,20(5):500-502. doi: 10.1111/j.1365-2125.1985.tb05107.x |
[5]
|
BIENVENU J, SANN L, BIENVENU F, et al. Laser nephelometry of orosomucoid in serum of newborns: reference intervals and relation to bacterial infections[J]. Clin Chem,1981,27(5):721-726. doi: 10.1093/clinchem/27.5.721 |
[6]
|
KREMER J M, WILTING J, JANSSEN L H. Drug binding to human alpha-1-acid glycoprotein in health and disease[J]. Pharmacol Rev,1988,40(1):1-47. |
[7]
|
UMETSU K, YUASA I, HARADA A, et al. Orosomucoid phenotyping with monoclonal antibodies: polymorphic occurrence of ORM1*Q0 in aboriginal Taiwanese populations[J]. Hum Hered,1995,45(4):181-185. doi: 10.1159/000154286 |
[8]
|
DENTE L, PIZZA M G, METSPALU A, et al. Structure and expression of the genes coding for human alpha 1-acid glycoprotein[J]. EMBO J,1987,6(8):2289-2296. doi: 10.1002/j.1460-2075.1987.tb02503.x |
[9]
|
YUASA I, UMETSU K, VOGT U, et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S[J]. Hum Genet,1997,99(3):393-398. doi: 10.1007/s004390050378 |
[10]
|
CARTER K C, POST D J, PAPACONSTANTINOU J. Differential expression of the mouse alpha 1-acid glycoprotein genes (AGP-1 and AGP-2) during inflammation and aging[J]. Biochim Biophys Acta,1991,1089(2):197-205. doi: 10.1016/0167-4781(91)90008-A |
[11]
|
COOPER R, PAPACONSTANTINOU J. Evidence for the existence of multiple alpha 1-acid glycoprotein genes in the mouse[J]. J Biol Chem,1986,261(4):1849-1853. doi: 10.1016/S0021-9258(17)36019-2 |
[12]
|
FITOS I, VISY J, ZSILA F, et al. Specific ligand binding on genetic variants of human alpha1-acid glycoprotein studied by circular dichroism spectroscopy[J]. Biochem Pharmacol,2004,67(4):679-688. doi: 10.1016/j.bcp.2003.09.039 |
[13]
|
SCHMID K, KAUFMANN H, ISEMURA S, et al. Structure of 1 -acid glycoprotein. The complete amino acid sequence, multiple amino acid substitutions, and homology with the immunoglobulins[J]. Biochemistry,1973,12(14):2711-2724. doi: 10.1021/bi00738a026 |
[14]
|
KOPECKÝ V Jr, ETTRICH R, HOFBAUEROVÁ K, et al. Structure of human alpha1-acid glycoprotein and its high-affinity binding site[J]. Biochem Biophys Res Commun,2003,300(1):41-46. doi: 10.1016/S0006-291X(02)02765-1 |
[15]
|
RICCA G A, HAMILTON R W, MCLEAN J W, et al. Rat alpha 1-acid glycoprotein mRNA. Cloning of double-stranded cDNA and kinetics of induction of mRNA levels following acute inflammation[J]. J Biol Chem,1981,256(20):10362-10368. doi: 10.1016/S0021-9258(19)68627-8 |
[16]
|
YOSHIMA H, MATSUMOTO A, MIZUOCHI T, et al. Comparative study of the carbohydrate moieties of rat and human plasma alpha 1-acid glycoproteins[J]. J Biol Chem,1981,256(16):8476-8484. doi: 10.1016/S0021-9258(19)68868-X |
[17]
|
SCHLEY J, MÜLLER-OERLINGHAUSEN B. Investigation of the binding of various tricyclic neuroleptics and antidepressants to alpha 1-acid glycoprotein[J]. J Pharm Pharmacol,1986,38(2):102-106. |
[18]
|
KERKAY J, WESTPHAL U. Steroid-protein interactions. XIX. Complex formation between alpha 1-acid glycoprotein and steroid hormones[J]. Biochim Biophys Acta,1968,170(2):324-333. doi: 10.1016/0304-4165(68)90012-3 |
[19]
|
WRIGHT J D, BOUDINOT F D, UJHELYI M R. Measurement and analysis of unbound drug concentrations[J]. Clin Pharmacokinet,1996,30(6):445-462. doi: 10.2165/00003088-199630060-00003 |
[20]
|
SCHMID K. Human plasma alpha 1-acid glycoprotein: biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism[J]. Prog Clin Biol Res,1989,300:7-22. |
[21]
|
EAP C B, CUENDET C, BAUMANN P. Orosomucoid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study[J]. Hum Genet,1988,80(2):183-185. doi: 10.1007/BF00702865 |
[22]
|
IIJIMA S, SHIBA K, KIMURA M, et al. Changes of alpha1-acid glycoprotein microheterogeneity in acute inflammation stages analyzed by isoelectric focusing using serum obtained postoperatively[J]. Electrophoresis,2000,21(4):753-759. doi: 10.1002/(SICI)1522-2683(20000301)21:4<753::AID-ELPS753>3.0.CO;2-Y |
[23]
|
PONGANIS K V, STANSKI D R. Factors affecting the measurement of lidocaine protein binding by equilibrium dialysis in human serum[J]. J Pharm Sci,1985,74(1):57-60. doi: 10.1002/jps.2600740115 |
[24]
|
WONG A K, HSIA J C. In vitro binding of propranolol and progesterone to native and desialylated human orosomucoid[J]. Revue Can De Biochimie et Biol Cell,1983,61(10):1114-1116. doi: 10.1139/o83-142 |
[25]
|
ASHWELL G, HARFORD J. Carbohydrate-specific receptors of the liver[J]. Annu Rev Biochem,1982,51:531-554. doi: 10.1146/annurev.bi.51.070182.002531 |
[26]
|
APWEILER R, HERMJAKOB H, SHARON N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database[J]. Biochim Biophys Acta,1999,1473(1):4-8. doi: 10.1016/S0304-4165(99)00165-8 |
[27]
|
LUO Z M, LEI H, SUN Y, et al. Orosomucoid, an acute response protein with multiple modulating activities[J]. J Physiol Biochem,2015,71(2):329-340. doi: 10.1007/s13105-015-0389-9 |
[28]
|
VAN DIJK W, HAVENAAR E C, BRINKMAN-VAN DER LINDEN E C. Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function[J]. Glycoconj J,1995,12(3):227-233. doi: 10.1007/BF00731324 |
[29]
|
KIM T, XIE Y, LI Q, et al. Diet affects glycosylation of serum proteins in women at risk for cardiometabolic disease[J]. Eur J Nutr,2021,60(7):3727-3741. doi: 10.1007/s00394-021-02539-7 |
[30]
|
BERGER E G, ALPERT E, SCHMID K, et al. Immunohistochemical localization of alpha1-acid-glycoprotein in human liver parenchymal cells[J]. Histochemistry,1977,51(4):293-296. doi: 10.1007/BF00494364 |
[31]
|
CECILIANI F, LECCHI C. The immune functions of α1 acid glycoprotein[J]. Curr Protein Pept Sci,2019,20(6):505-524. doi: 10.2174/1389203720666190405101138 |
[32]
|
ALAM T, PAPACONSTANTINOU J. Interaction of acute-phase-inducible and liver-enriched nuclear factors with the promoter region of the mouse. alpha. 1-acid glycoprotein gene-1[J]. Biochemistry,1992,31(7):1928-1936. doi: 10.1021/bi00122a005 |
[33]
|
BAUMANN H, GAULDIE J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation[J]. Mol Biol Med,1990,7(2):147-159. |
[34]
|
WIGMORE S J, FEARON K C, MAINGAY J P, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes[J]. Am J Physiol,1997,273(4):E720-E726. |
[35]
|
SMITH S A, WATERS N J. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein[J]. Pharm Res,2018,36(2):30. |
[36]
|
LEFEBVRE P, CARIOU B, LIEN F, et al. Role of bile acids and bile acid receptors in metabolic regulation[J]. Physiol Rev,2009,89(1):147-191. doi: 10.1152/physrev.00010.2008 |
[37]
|
POREZ G, GROSS B, PRAWITT J, et al. The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR[J]. Endocrinology,2013,154(10):3690-3701. doi: 10.1210/en.2013-1263 |
[38]
|
CHANG C J, CHEN T T, LEI H Y, et al. Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family[J]. Mol Cell Biol,1990,10(12):6642-6653. |
[39]
|
YANG T H, TSAI W H, LEE Y M, et al. Purification and characterization of nucleolin and its identification as a transcription repressor[J]. Mol Cell Biol,1994,14(9):6068-6074. |
[40]
|
LEE Y M, TSAI W H, LAI M Y, et al. Induction of liver alpha-1 acid glycoprotein gene expression involves both positive and negative transcription factors[J]. Mol Cell Biol,1993,13(1):432-442. |
[41]
|
SUN Y, QIN Z, WAN J J, et al. Estrogen weakens muscle endurance via estrogen receptor-p38 MAPK-mediated orosomucoid (ORM) suppression[J]. Exp Mol Med,2018,50(3):e463. doi: 10.1038/emm.2017.307 |
[42]
|
LEE S H, CHOI J M, JUNG S Y, et al. The bile acid induced hepatokine orosomucoid suppresses adipocyte differentiati-on[J]. Biochem Biophys Res Commun,2021,534:864-870. doi: 10.1016/j.bbrc.2020.10.086 |
[43]
|
SHI M J, MA X R, YANG Q, et al. miR-362-3p targets orosomucoid 1 to promote cell proliferation, restrain cell apoptosis and thereby mitigate hypoxia/reoxygenation-induced cardiomyocytes injury[J]. Cardiovasc Toxicol,2021,21(5):387-398. doi: 10.1007/s12012-020-09631-0 |
[44]
|
LIN T H, SUGIYAMA Y, SAWADA Y, et al. Effect of surgery on serum alpha 1-acid glycoprotein concentration and serum protein binding of DL-propranolol in phenobarbital-treated and untreated rats[J]. Drug Metab Dispos,1987,15(1):138-140. |
[45]
|
MOUTHIERS A, MEJDOUBI N, BAILLET A, et al. Retinoids increase alpha-1 acid glycoprotein expression at the transcriptional level through two distinct DR1 retinoic acid responsive elements[J]. Biochim Biophys Acta,2004,1678(2-3):135-144. doi: 10.1016/j.bbaexp.2004.03.005 |
[46]
|
MEJDOUBI N, HENRIQUES C, BUI E, et al. NF-kappaB is involved in the induction of the rat hepatic alpha1-acid glycoprotein gene by phenobarbital[J]. Biochem Biophys Res Commun,1999,254(1):93-99. doi: 10.1006/bbrc.1998.9903 |
[47]
|
GEMELLI C, MARTELLO A, MONTANARI M, et al. The Orosomucoid 1 protein is involved in the vitamin D - mediated macrophage de-activation process[J]. Exp Cell Res,2013,319(20):3201-3213. doi: 10.1016/j.yexcr.2013.08.017 |
[48]
|
KOMORI T, KAI H, SHIMOISHI K, et al. Up-regulation by clarithromycin of alpha(1)-acid glycoprotein expression in liver and primary cultured hepatocytes[J]. Biochem Pharmacol,2001,62(10):1391-1397. doi: 10.1016/S0006-2952(01)00778-X |
[49]
|
WAN J J, QIN Z, LEI H, et al. Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance[J]. Pharmacol Res,2020,161:105118. doi: 10.1016/j.phrs.2020.105118 |
[50]
|
FANDIÑO-VAQUERO R, FERNÁNDEZ-TRASANCOS A, ÁLVAREZ E, et al. Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease[J]. Atherosclerosis,2014,235(2):281-288. doi: 10.1016/j.atherosclerosis.2014.05.921 |
[51]
|
HUANG Z, XU A M. Adipose extracellular vesicles in intercellular and inter-organ crosstalk in metabolic health and diseases[J]. Front Immunol,2021,12:608680. doi: 10.3389/fimmu.2021.608680 |
[52]
|
LEE Y S, CHOI J W, HWANG I, et al. Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation[J]. J Biol Chem,2010,285(29):22174-22185. doi: 10.1074/jbc.M109.085464 |
[53]
|
SUN Y, YANG Y L, QIN Z, et al. The acute-phase protein orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway[J]. Diabetes,2016,65(6):1630-1641. doi: 10.2337/db15-1193 |
[54]
|
RAMSAY T G, BLOMBERG L, CAPERNA T J. Α 1-acid glycoprotein inhibits lipogenesis in neonatal swine adipose tissue[J]. Animal,2016,10(5):812-820. doi: 10.1017/S1751731115002414 |
[55]
|
WANG P Y, FENG J Y, ZHANG Z, et al. The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathway[J]. Acta Pharmacol Sin,2021. doi: 10.1038/s41401-021-00666-9 |
[56]
|
ATAKAN M M, KOŞAR Ş N, GÜZEL Y, et al. The role of exercise, diet, and cytokines in preventing obesity and improving adipose tissue[J]. Nutrients,2021,13(5):1459. doi: 10.3390/nu13051459 |
[57]
|
CARLSON L A, TIGHE S W, KENEFICK R W, et al. Changes in transcriptional output of human peripheral blood mononuclear cells following resistance exercise[J]. Eur J Appl Physiol,2011,111(12):2919-2929. doi: 10.1007/s00421-011-1923-2 |
[58]
|
TÉKUS É, VÁCZI M, HORVÁTH-SZALAI Z, et al. Plasma actin, gelsolin and orosomucoid levels after eccentric exercise[J]. J Hum Kinet,2017,56:99-108. doi: 10.1515/hukin-2017-0027 |
[59]
|
RAMSAY T G, BLOMBERG L A, ELSASSER T H, et al. Α-1 acid glycoprotein inhibits insulin responses by glucose oxidation, protein synthesis and protein breakdown in mouse C2C12 myotubes[J]. Animal,2019,13(4):771-776. doi: 10.1017/S1751731118001787 |
[60]
|
LEI H, SUN Y, LUO Z, et al. Fatigue-induced orosomucoid 1 Acts on C-C chemokine receptor type 5 to enhance muscle endurance[J]. Sci Rep,2016,6:18839. doi: 10.1038/srep18839 |
[61]
|
HARDIE D G, ROSS F A, HAWLEY S A. AMPK: a nutrient and energy sensor that maintains energy homeostasis[J]. Nat Rev Mol Cell Biol,2012,13(4):251-262. |
[62]
|
DAVAL M, FOUFELLE F, FERRÉ P. Functions of AMP-activated protein kinase in adipose tissue[J]. J Physiol,2006,574(Pt1):55-62. |
[63]
|
EL-BEBLAWY N M, ANDRAWES N G, ISMAIL E A, et al. Serum and urinary orosomucoid in young patients with type 1 diabetes: a link between inflammation, microvascular complications, and subclinical atherosclerosis[J]. Clin Appl Thromb Hemost,2016,22(8):718-726. doi: 10.1177/1076029616637185 |
[64]
|
CAO Y N, LI L, XU M, et al. The ChinaMAP analytics of deep whole genome sequences in 10, 588 individuals[J]. Cell Res,2020,30(9):717-731. doi: 10.1038/s41422-020-0322-9 |
[65]
|
PETTERSSON-PABLO P, NILSSON T K, BREIMER L H, et al. Body fat percentage is more strongly associated with biomarkers of low-grade inflammation than traditional cardiometabolic risk factors in healthy young adults - the Lifestyle, Biomarkers, and Atherosclerosis study[J]. Scand J Clin Lab Invest,2019,79(3):182-187. doi: 10.1080/00365513.2019.1576219 |
[66]
|
WIKLUND P K, PEKKALA S, AUTIO R, et al. Serum metabolic profiles in overweight and obese women with and without metabolic syndrome[J]. Diabetol Metab Syndr,2014,6(1):40. doi: 10.1186/1758-5996-6-40 |
[67]
|
SUN Y, ZHANG Z X, LIU X. Orosomucoid (ORM) as a potential biomarker for the diagnosis of chronic fatigue syndrome (CFS)[J]. CNS Neurosci Ther,2016,22(3):251-252. doi: 10.1111/cns.12522 |
[68]
|
CAN U, BUYUKINAN M, GUZELANT A, et al. Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents[J]. J Pediatr Endocrinol Metab,2016,29(11):1277-1283. |
[69]
|
PALMNÄS M S A, KOPCIUK K A, SHAYKHUTDINOV R A, et al. Serum metabolomics of activity energy expenditure and its relation to metabolic syndrome and obesity[J]. Sci Rep,2018,8(1):3308. doi: 10.1038/s41598-018-21585-6 |